Immunophenotyping, microbiome, clinical outcome, and biomarkers to predict response in patients with high-grade cervical intraepithelial lesion treated with imiquimod

• Grant number: 23/09153-6
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2024
• End date: January 31, 2027
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Ricardo dos Reis
• Grantee: Ricardo dos Reis
• Host Institution: Hospital do Câncer de Barretos. Fundação Pio XII (FP). Barretos , SP, Brazil
• Associated researchers: Fabiana Albani Zambuzi ; Júlio César Possati Resende ; Lidia Maria Rebolho Batista Arantes ; Rui Manuel Vieira Reis
• Associated scholarship(s): 25/07290-1 - Immunophenotyping, microbiome, clinical outcome, and biomarkers to predict response in patients with high-grade cervical intraepithelial lesion treated with imiquimod, BP.TT

Abstract

INTRODUCTION: High-grade intraepithelial lesions (CIN 2/3) are considered precursor lesions of cervical cancer, and its treatment involves destructive or excisional methods. Some studies have proven the efficacy of the immunomodulator imiquimod as a topical treatment for CIN 2/3 lesions. Imiquimod activates the innate immune response through dendritic cells, monocytes and macrophages, in addition to modulating the response pattern of T lymphocytes. Thus, the characterization of the immune response in the treatment with imiquimod in lesions caused by oncogenic HPV, may benefit women in a way that it is possible to measure the response of each patient, improving the understanding of its mechanism of action, directly impacting the efficacy and adverse events. caused by the drug. OBJECTIVES: To identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. MATERIALS AND METHODS: It will be included 90 patients, 60 with high-risk HPV, diagnosed with CIN 3 and 30 patients with negative cytology and HPV. Patients will be divided into 3 groups: 1) patients with CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week; 2) patients with CIN 3 who will undergo standard treatment with Transformation Zone Excision (EZT); 3) patients with negative cytology and HPV. Blood and cervicovaginal lavage will be collected for immunophenotypic analysis (flow cytometry), quantification of immunological mediators (Cytometric Bead Array) and evaluation of the microbiome (MiniION). The results obtained will be correlated with the clinical and pathological data of the patients. (AU)